Philip J Hogg

List of Publications by Year
in descending order

144 papers	7,399 citations	53794 45 h-index	58581 82 g-index
151 all docs	151 docs citations	151 times ranked	7823 citing authors

#	Article	IF	Citations
1	Not one, but many forms of thrombosis proteins. Journal of Thrombosis and Haemostasis, 2022, 20, 285-292.	3.8	3
2	Preclinical Assessment of [68Ga]Ga-Cell Death Indicator (CDI): A Novel hsp90 Ligand for Positron Emission Tomography of Cell Death. Current Radiopharmaceuticals, 2022, 15, 184-193.	0.8	2
3	A first-in-human study of [68Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4037-4047.	6.4	2
4	A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2021, 87, 613-620.	2.3	0
5	Toxicokinetics of the tumour cell mitochondrial toxin, PENAO, in rodents. Investigational New Drugs, 2021, 39, 756-763.	2.6	1
6	Influenza A Virus Hemagglutinin Is Produced in Different Disulfide-Bonded States. Antioxidants and Redox Signaling, 2021, 35, 1081-1092.	5.4	2
7	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	2.3	2
8	An alternate covalent form of platelet Î±IIbÎ²3 integrin that resides in focal adhesions and has altered function. Blood, 2021, 138, 1359-1372.	1.4	8
9	PDI Cleavage of Disulfide Bonds within the TP Receptor Inhibits Signaling through GÎ± 13. Blood, 2021, 138, 579-579.	1.4	1
10	Protein Disulphide Isomerase 6 (PDIA6) Attenuates Platelet Endoplasmic Reticulum Stress and Secretion in a Mouse Model. Blood, 2021, 138, 3138-3138.	1.4	0
11	Reprogramming of human fibroblasts into osteoblasts by insulin-like growth factor-binding protein 7. Stem Cells Translational Medicine, 2020, 9, 403-415.	3.3	17
12	Regulation of hepatic insulin signaling and glucose homeostasis by sphingosine kinase 2. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24434-24442.	7.1	29
13	Multiple Disulfide-Bonded States of Native Proteins: Estimate of Number Using Probabilities of Disulfide Bond Formation. Molecules, 2020, 25, 5729.	3.8	7
14	Fibrinogen function achieved through multiple covalent states. Nature Communications, 2020, 11, 5468.	12.8	20
15	The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas. Oncotarget, 2020, 11, 46-61.	1.8	1
16	Biodistribution and imaging of an hsp90 ligand labelled with 111In and 67Ga for imaging of cell death. EJNMMI Research, 2020, 10, 4.	2.5	3
17	Extracellular Protein Disulfide Isomerase Cleaves Allosteric Disulfides in Histidine-Rich Glycoprotein to Regulate Thrombus Formation. Blood, 2020, 136, 11-12.	1.4	0
18	Thiol isomerase ERp57 targets and modulates the lectin pathway of complement activation. Journal of Biological Chemistry, 2019, 294, 4878-4888.	3.4	12

#	Article	IF	Citations
19	TMX1: a new vascular thiol isomerase. Blood, 2019, 133, 188-190.	1.4	3
20	Preparation of a Dithiol-Reactive Probe for PET Imaging of Cell Death. Methods in Molecular Biology, 2019, 1967, 295-304.	0.9	6
21	Global redox proteome and phosphoproteome analysis reveals redox switch in Akt. Nature Communications, 2019, 10, 5486.	12.8	89
22	Platelet Protein Disulfide Isomerase Promotes Glycoprotein IbÎ±â€“Mediated Platelet-Neutrophil Interactions Under Thromboinflammatory Conditions. Circulation, 2019, 139, 1300-1319.	1.6	63
23	JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. Leukemia, 2019, 33, 1400-1410.	7.2	31
24	Allosteric disulfides: Sophisticated molecular structures enabling flexible protein regulation. Journal of Biological Chemistry, 2019, 294, 2949-5908.	3.4	95
25	Classification of Protein Disulphide Bonds. Methods in Molecular Biology, 2019, 1967, 1-8.	0.9	3
26	Autoregulation of von Willebrand factor function by a disulfide bond switch. Science Advances, 2018, 4, eaaq1477.	10.3	79
27	Direct Polymerization of the Arsenic Drug PENAO to Obtain Nanoparticles with High Thiol-Reactivity and Anti-Cancer Efficiency. Bioconjugate Chemistry, 2018, 29, 546-558.	3.6	16
28	Î³-Crystallin redoxâ€“detox in the lens. Journal of Biological Chemistry, 2018, 293, 18010-18011.	3.4	15
29	Identification of allosteric disulfides from labile bonds in X-ray structures. Royal Society Open Science, 2018, 5, 171058.	2.4	17
30	Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma. Oncotarget, 2018, 9, 7541-7556.	1.8	29
31	Mechano-redox control of integrin de-adhesion. ELife, 2018, 7, .	6.0	47
32	CHAPTER 2.3. Allosteric Disulfide Bonds. Chemical Biology, 2018, , 152-174.	0.2	1
33	One-Way Allosteric Communication between the Two Disulfide Bonds in Tissue Factor. Biophysical Journal, 2017, 112, 78-86.	0.5	7
34	Zinc is a potent and specific inhibitor of IFN-Î»3 signalling. Nature Communications, 2017, 8, 15245.	12.8	47
35	A substrate-driven allosteric switch that enhances PDI catalytic activity. Nature Communications, 2016, 7, 12579.	12.8	98
36	Protein Disulfide Isomerase in Thrombosis. Seminars in Thrombosis and Hemostasis, 2015, 41, 765-773.	2.7	20

#	Article	IF	Citations
37	Necrotic platelets provide a procoagulant surface during thrombosis. Blood, 2015, 126, 2852-2862.	1.4	83
38	Sulfur Derivatives of the Natural Polyarsenical Arsenicin A: Biologically Active, Organometallic Arsenicâ€"Sulfur Cages Related to the Minerals Realgar and Uzonite. Organometallics, 2015, 34, 829-840.	2.3	9
39	Dual-targeting of aberrant glucose metabolism in glioblastoma. Journal of Experimental and Clinical Cancer Research, 2015, 34, 14.	8.6	41
40	Organic Arsenicals As Efficient and Highly Specific Linkers for Protein/Peptideâ€"Polymer Conjugation. Journal of the American Chemical Society, 2015, 137, 4215-4222.	13.7	71
41	Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells. Gynecologic Oncology, 2015, 138, 363-371.	1.4	17
42	Platelet Surface PDI Controls the Ligand-Binding Function of Glycoprotein Ibalpha and Platelet-Neutrophil Interactions Under Thromboinflammatory Conditions. Blood, 2015, 126, 235-235.	1.4	0
43	Redox Regulation of Methionine Aminopeptidase 2 Activity. Journal of Biological Chemistry, 2014, 289, 15035-15043.	3.4	20
44	Targeting of two aspects of metabolism in breast cancer treatment. Cancer Biology and Therapy, 2014, 15, 1533-1541.	3.4	32
45	Mechanism of Dimerization of a Recombinant Mature Vascular Endothelial Growth Factor C. Biochemistry, 2014, 53, 7-9.	2.5	19
46	Characterization of a Reduced Form of Plasma Plasminogen as the Precursor for Angiostatin Formation. Journal of Biological Chemistry, 2014, 289, 2992-3000.	3.4	16
47	Employing Pancreatic Tumor Î³-Glutamyltransferase for Therapeutic Delivery. Molecular Pharmaceutics, 2014, 11, 1500-1511.	4.6	13
48	Control of blood proteins by functional disulfide bonds. Blood, 2014, 123, 2000-2007.	1.4	83
49	Optical imaging of cell death in traumatic brain injury using a heat shock protein-90 alkylator. Cell Death and Disease, 2013, 4, e473-e473.	6.3	20
50	A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2013, 72, 1343-1352.	2.3	33
51	Tyrosine nitration moderates the peptidase activity of human methionyl aminopeptidase 2. Biochemical and Biophysical Research Communications, 2013, 440, 37-42.	2.1	6
52	Post-Translational Control of Protein Function by Disulfide Bond Cleavage. Antioxidants and Redox Signaling, 2013, 18, 1987-2015.	5.4	94
53	Targeting allosteric disulphide bonds in cancer. Nature Reviews Cancer, 2013, 13, 425-431.	28.4	73
54	Optical Imaging of Treatment-Related Tumor Cell Death Using a Heat Shock Protein-90 Alkylator. Molecular Pharmaceutics, 2013, 10, 3882-3891.	4.6	18

#	Article	IF	Citations
55	Elimination of the antimicrobial action of the organoarsenical cancer therapeutic, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid, before finished product sterility testing. Journal of Pharmacy and Pharmacology, 2013, 65, 1664-1669.	2.4	3
56	Allosteric Control of Î²II-Tryptase by a Redox Active Disulfide Bond. Journal of Biological Chemistry, 2013, 288, 34920-34929.	3.4	21
57	Procoagulant Role Of Necrotic Platelets Demonstrated Using Novel Platelet Necrosis Marker. Blood, 2013, 122, 3512-3512.	1.4	0
58	Factor XI is a substrate for oxidoreductases: Enhanced activation of reduced FXI and its role in antiphospholipid syndrome thrombosis. Journal of Autoimmunity, 2012, 39, 121-129.	6.5	41
59	The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase. Cancer Cell International, 2012, 12, 11.	4.1	46
60	Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for Phase I clinical trial. International Journal of Pharmaceutics, 2012, 426, 67-75.	5.2	16
61	Noninvasive Imaging of Cell Death Using an Hsp90 Ligand. Journal of the American Chemical Society, 2011, 133, 2832-2835.	13.7	56
62	Disulfide Bond Acquisition through Eukaryotic Protein Evolution. Molecular Biology and Evolution, 2011, 28, 327-334.	8.9	83
63	Control of Mature Protein Function by Allosteric Disulfide Bonds. Antioxidants and Redox Signaling, 2011, 14, 113-126.	5.4	40
64	Redox properties of the tissue factor Cys186â€"Cys209 disulfide bond. Biochemical Journal, 2011, 437, 455-460.	3.7	34
65	Lateral self-association of VWF involves the Cys2431-Cys2453 disulfide/dithiol in the C2 domain. Blood, 2011, 118, 5312-5318.	1.4	47
66	Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine 2,3-dioxygenase in monocyte-derived endothelial-like cells: possible relevance to infantile haemangioma pathogenesis. British Journal of Dermatology, 2011, 164, 308-315.	1.5	40
67	Mitochondrial Metabolism Inhibitors for Cancer Therapy. Pharmaceutical Research, 2011, 28, 2731-2744.	3.5	45
68	Reactive Oxygen Species and p38 Mitogen-activated Protein Kinase Mediate Tumor Necrosis Factor Î±-Converting Enzyme (TACE/ADAM-17) Activation in Primary Human Monocytes. Journal of Biological Chemistry, 2011, 286, 35466-35476.	3.4	95
69	Allosteric Disulfide Bonds. , 2011, , 151-182.		3
70	Naturally occurring free thiols within Î²2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stressâ€"induced cell injury. Blood, 2010, 116, 1961-1970.	1.4	105
71	Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood, 2010, 116, 1995-1997.	1.4	60
72	Analysis of disulfide bonds in protein structures. Journal of Thrombosis and Haemostasis, 2010, 8, 2345.	3.8	30

#	Article	IF	Citations
73	Disulfide Bond That Constrains the HIV-1 gp120 V3 Domain Is Cleaved by Thioredoxin. Journal of Biological Chemistry, 2010, 285, 40072-40080.	3.4	31
74	Reduced Monomeric CD4 Is the Preferred Receptor for HIV. Journal of Biological Chemistry, 2010, 285, 40793-40799.	3.4	31
75	Optimization of the Antitumor Efficacy of a Synthetic Mitochondrial Toxin by Increasing the Residence Time in the Cytosol. Journal of Medicinal Chemistry, 2009, 52, 6209-6216.	6.4	39
76	Direct effects of alcohol on hepatic fibrinolytic balance: Implications for alcoholic liver disease. Journal of Hepatology, 2008, 48, 614-627.	3.7	48
77	Insight into the selectivity of arsenic trioxide for acute promyelocytic leukemia cells by characterizing Saccharomyces cerevisiae deletion strains that are sensitive or resistant to the metalloid. International Journal of Biochemistry and Cell Biology, 2008, 40, 1016-1029.	2.8	29
78	Metabolism of the Tumor Angiogenesis Inhibitor 4-(N-(S-Glutathionylacetyl)amino)phenylarsonous Acid. Journal of Biological Chemistry, 2008, 283, 35428-35434.	3.4	36
79	Critical importance of the cell system when studying tissue factor de-encryption. Blood, 2008, 112, 912-913.	1.4	25
80	Arsenical-based cancer drugs. Cancer Treatment Reviews, 2007, 33, 542-564.	7.7	339
81	Search for allosteric disulfide bonds in NMR structures. BMC Structural Biology, 2007, 7, 49.	2.3	68
82	Allosteric Disulfide Bonds. Biochemistry, 2006, 45, 7429-7433.	2.5	309
83	Evidence for Activation of Tissue Factor by an Allosteric Disulfide Bondâ€. Biochemistry, 2006, 45, 12020-12028.	2.5	176
84	Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 13932-13937.	7.1	324
85	Evidence for a Domain-Swapped CD4 Dimer as the Coreceptor for Binding to Class II MHC. Journal of Immunology, 2006, 176, 6873-6878.	0.8	42
86	Allosteric Disulfide Bonds in Thrombosis and Thrombolysis.. Blood, 2006, 108, 4036-4036.	1.4	1
87	Para to Ortho Repositioning of the Arsenical Moiety of the Angiogenesis Inhibitor 4-(N-(S-Glutathionylacetyl)Amino)Phenylarsenoxide Results in a Markedly Increased Cellular Accumulation and Antiproliferative Activity. Cancer Research, 2005, 65, 11729-11734.	0.9	17
88	Mechanism of Selectivity of an Angiogenesis Inhibitor From Screening a Genome-Wide Set of Saccharomyces cerevisiae Deletion Strains. Journal of the National Cancer Institute, 2005, 97, 1539-1547.	6.3	34
89	Tissue Factor Activation Involves Disulfide Switching.. Blood, 2005, 106, 684-684.	1.4	9
90	Molecular Switch between Tissue Factor-Mediated Signaling and Coagulation.. Blood, 2005, 106, 685-685.	1.4	3

#	Article	IF	Citations
91	Mechanism of Selectivity of Arsenic Trioxide for Acute Promyelocytic Leukemia Cells from Screening a Genome Wide Set of Saccharomyces cerevisiae Deletion Strains.. Blood, 2005, 106, 2470-2470.	1.4	0
92	Evidence for Control of von Willebrand Factor Multimer Size by Intramolecular Thiol-Disulfide Exchange.. Blood, 2005, 106, 412-412.	1.4	0
93	Role of Thrombospondin-1 in Control of von Willebrand Factor Multimer Size in Mice. Journal of Biological Chemistry, 2004, 279, 21439-21448.	3.4	51
94	Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1691, 17-22.	4.1	54
95	Cross-strand disulphides in cell entry proteins: poised to act. BioEssays, 2004, 26, 73-79.	2.5	61
96	Mitochondria as cancer drug targets. Trends in Molecular Medicine, 2004, 10, 372-378.	6.7	120
97	Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood, 2004, 103, 627-629.	1.4	84
98	Disulfide bonds as switches for protein function. Trends in Biochemical Sciences, 2003, 28, 210-214.	7.5	530
99	A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell, 2003, 3, 497-509.	16.8	145
100	A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura. European Journal of Haematology, 2003, 70, 257-262.	2.2	6
101	Thrombospondin-1 inhibits in vitro megakaryocytopoiesis via CD36. Thrombosis Research, 2003, 109, 47-54.	1.7	24
102	Protein-Protein Interaction between Fli-1 and GATA-1 Mediates Synergistic Expression of Megakaryocyte-Specific Genes through Cooperative DNA Binding. Molecular and Cellular Biology, 2003, 23, 3427-3441.	2.3	114
103	Protein profiles associated with survival in lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13537-13542.	7.1	262
104	Redox Control on the Cell Surface: Implications for HIV-1 Entry. Antioxidants and Redox Signaling, 2003, 5, 133-138.	5.4	43
105	[10] Measurement of reduction of disulfide bonds in plasmin by phosphoglycerate kinase. Methods in Enzymology, 2002, 348, 87-92.	1.0	4
106	Plasmin Reduction by Phosphoglycerate Kinase Is a Thiol-independent Process. Journal of Biological Chemistry, 2002, 277, 9062-9068.	3.4	35
107	[9] Characterization of redox-active proteins on cell surface. Methods in Enzymology, 2002, 348, 76-86.	1.0	9
108	Biological regulation through protein disulfide bond cleavage. Redox Report, 2002, 7, 71-77.	4.5	26

#	Article	IF	Citations
109	Building an ER electron transport chain. Redox Report, 2002, 7, 3-4.	4.5	4
110	The von Willebrand factorâ€"reducing activity of thrombospondin-1 is located in the calcium-binding/C-terminal sequence and requires a free thiol at position 974. Blood, 2002, 100, 2832-2838.	1.4	34
111	Blood vessels and nerves: together or not?. Lancet, The, 2002, 360, 1714.	13.7	8
112	Control of von Willebrand factor multimer size and implications for disease. Blood Reviews, 2002, 16, 185-192.	5.7	18
113	Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nature Immunology, 2002, 3, 727-732.	14.5	177
114	Identification and Characterisation of a Platelet GPIb/V/IX-like Complex on Human Breast Cancers: Implications for the Metastatic Process. Japanese Journal of Cancer Research, 2001, 92, 1082-1092.	1.7	21
115	Control of Von Willebrand Factor Multimer Size by Thrombospondin-1. Journal of Experimental Medicine, 2001, 193, 1341-1350.	8.5	126
116	Lupus Antibody Bivalency Is Required to Enhance Prothrombin Binding to Phospholipid. Journal of Immunology, 2001, 166, 6118-6125.	0.8	31
117	Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature, 2000, 408, 869-873.	27.8	264
118	Presence of closely spaced protein thiols on the surface of mammalian cells. Protein Science, 2000, 9, 2436-2445.	7.6	110
119	Physical Proximity and Functional Association of Glycoprotein 1bÎ± and Protein-disulfide Isomerase on the Platelet Plasma Membrane. Journal of Biological Chemistry, 2000, 275, 9758-9766.	3.4	119
120	Lupus Anticoagulants Form Immune Complexes With Prothrombin and Phospholipid That Can Augment Thrombin Production in Flow. Blood, 1999, 94, 3421-3431.	1.4	29
121	Redox Control of Exofacial Protein Thiols/Disulfides by Protein Disulfide Isomerase. Journal of Biological Chemistry, 1999, 274, 2416-2423.	3.4	160
122	Angiostatin Formation Involves Disulfide Bond Reduction and Proteolysis in Kringle 5 of Plasmin. Journal of Biological Chemistry, 1999, 274, 8910-8916.	3.4	78
123	Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids. Biochemical Journal, 1999, 340, 59-67.	3.7	25
124	Exposure of the cryptic Arg-Gly-Asp sequence in thrombospondin-1 by protein disulfide isomerase. BBA - Proteins and Proteomics, 1998, 1388, 478-488.	2.1	69
125	Evidence for multiple enzyme site involvement in the modulation of thrombin activity by products of prothrombin proteolysis. Biophysical Chemistry, 1998, 75, 187-199.	2.8	9
126	Generation of Angiostatin by Reduction and Proteolysis of Plasmin. Journal of Biological Chemistry, 1997, 272, 20641-20645.	3.4	142

#	Article	IF	Citations
127	Interaction of platelet-derived growth factor with thrombospondin 1. Biochemical Journal, 1997, 326, 709-716.	3.7	53
128	Significant correlation between thrombospondin 1 and serine proteinase expression in rheumatoid synovium. Arthritis and Rheumatism, 1997, 40, 1780-1787.	6.7	26
129	Modulation of Thrombin and Heparin Activities by Fibrin. Thrombosis and Haemostasis, 1997, 77, 424-433.	3.4	37
130	Catalysis of Disulfide Isomerization in Thrombospondin 1 by Protein Disulfide Isomerase. Biochemistry, 1996, 35, 9761-9767.	2.5	51
131	Extracellular matrix is a source of mitogenically active platelet-derived growth factor. , 1996, 168, 322-332.		17
132	Binding of Fibrin Monomer and Heparin to Thrombin in a Ternary Complex Alters the Environment of the Thrombin Catalytic Site, Reduces Affinity for Hirudin, and Inhibits Cleavage of Fibrinogen. Journal of Biological Chemistry, 1996, 271, 26088-26095.	3.4	48
133	Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells. Thrombosis Research, 1995, 79, 353-361.	1.7	6
134	Thrombospondin 1 as an Enzyme Inhibitor. Thrombosis and Haemostasis, 1994, 72, 787-792.	3.4	62
135	Anticardiolipin Antibodies Block the Inhibition by Î²2-Glycoprotein I of the Factor Xa Generating Activity of Platelets. Thrombosis and Haemostasis, 1993, 70, 342-345.	3.4	91
136	Modulation of Fibrinolysis by Thrombospondin. Annals of the New York Academy of Sciences, 1992, 667, 64-69.	3.8	23
137	Interaction of human protein Z with thrombin: Evaluation of the species difference in the interaction between bovine and human protein Z and thrombin. Biochemical and Biophysical Research Communications, 1991, 178, 801-807.	2.1	30
138	Use of quantitative affinity chromatography for characterizing high-affinity interactions: Binding of heparin to antithrombin III. Analytical Biochemistry, 1991, 192, 303-311.	2.4	20
139	Evaluation of equilibrium constants for antigen-antibody interactions by solid-phase immunoassay: The binding of paraquat to its elicited mouse monoclonal antibody. Molecular Immunology, 1987, 24, 797-801.	2.2	79
140	Further probes into quantitative aspects of competitive binding assays: Allowance for effects of antigen multivalency in immunoassays. Archives of Biochemistry and Biophysics, 1987, 254, 92-101.	3.0	14
141	Studies of lectin-carbohydrate interactions by quantitative affinity chromatography: Systems with galactose and ovalbumin as saccharidic ligand. Analytical Biochemistry, 1987, 163, 331-338.	2.4	21
142	Effects of solute multivalency in quantitative affinity chromatography: Evidence for cooperative binding of horse liver alcohol dehydrogenase to Blue Sepharose. Archives of Biochemistry and Biophysics, 1985, 240, 70-76.	3.0	21
143	Evidence for the preferential interaction of micellar chlorpromazine with human serum albumin. Biochemical Pharmacology, 1984, 33, 1998-2000.	4.4	6
144	Quantitative affinity chromatography: Further developments in the analysis of experimental results from column chromatography and partition equilibrium studies. Archives of Biochemistry and Biophysics, 1984, 234, 55-60.	3.0	46